muvalaplin
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 2, 2025 (NCT07157774)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Apolipoprotein A-IINHIBITOR
APOA1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)[C@@H](Cc1cccc(CN(Cc2cccc(C[C@H](C(=O)O)[C@H]3CCNC3)c2)Cc2cccc(C[C@H](C(=O)O)[C@H]3CCNC3)c2)c1)[C@H]1CCNC1- Mol. weight
- 710.92 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802585 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07157774 | Phase 3 | Sep 2, 2025 | Eli Lilly |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1